Neurogene Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NGNE Nasdaq 2836 www.neurogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Neurogene Inc.

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Jan 12th, 2026 5:00 am
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 5:30 am
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 4th, 2025 2:01 pm
Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth - Nov 26th, 2025 3:51 am
Neurogene: Q3 Earnings Snapshot - Nov 13th, 2025 3:21 pm
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates - Nov 13th, 2025 3:10 pm
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome - Nov 12th, 2025 2:01 pm
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome - Nov 6th, 2025 5:30 am
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 5th, 2025 2:01 pm
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025 - Oct 9th, 2025 5:00 am
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - Oct 8th, 2025 5:30 am
Neurogene: Q2 Earnings Snapshot - Aug 11th, 2025 3:55 pm
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates - Aug 11th, 2025 2:10 pm
Bullish Neurogene Insiders Loaded Up On US$1.46m Of Stock - Jul 30th, 2025 4:14 am
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Jun 30th, 2025 2:01 pm
Craig-Hallum bullish on Neurogene, initiates with a Buy - Jun 18th, 2025 7:16 am
Short Report: Bears bite into Krispy Kreme after another weak earnings report - May 26th, 2025 9:15 am
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - May 16th, 2025 5:00 am
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - May 9th, 2025 5:30 am
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting - Apr 28th, 2025 3:00 pm